Navigation Links
Amylin Pharmaceuticals to Webcast Year-End Financial Results
Date:1/19/2011

SAN DIEGO, Jan. 19, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2010 on Wednesday, January 26, 2011 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the fourth quarter and year ended December 31, 2010.  

The call will be webcast live through the "Investor's" section of Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (800) 857-5738 (U.S./Canada) or (415) 228-4970 (international), participant passcode number 75593. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 567-0472 (U.S./Canada) or (203) 369-3447 (international).

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
5. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
6. Amylin Pharmaceuticals to Webcast Third Quarter Results
7. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
8. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
9. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Webcast Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... SYK ) reported operating results for the quarter ... Third Quarter Highlights Net sales increased 7.0% ... million Orthopaedic Implants sales increased 1.3% on a constant ... increased 16.3% on a constant currency basis (16.1% as reported) ...
... Initiatives, Inc. (Nasdaq: MTXX ), an over-the-counter healthcare ... second quarter and six months ended September 30, 2010, will ... 2010. An earnings conference call will be held the following ... To access the teleconference, please call (877) 718-5108 ...
Cached Medicine Technology:Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results 2
(Date:12/26/2014)... Los Angeles, CA (PRWEB) December 26, 2014 ... buyer power score of 3.1 out of 5. This ... from a low level of product specialization, low switching ... buyer power is reduced by the low availability of ... in the world price of steel and aluminum, key ...
(Date:12/26/2014)... Texas (PRWEB) December 26, 2014 Yisrayl Hawkins, ... written an open letter in light of the Ferguson, Missouri ... history of civil unrest and explains why it has only ... reason mankind was even created. He says there is a ... detail. Yisrayl also says there is a set of rules, ...
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... Plugin and template developers from Pixel Film ... Final Cut Pro X. , “TransPack Volume 5 gives users ... off an industry professional look” Said Christina Austin, CEO of ... Volume 5, a new level of professionalism will become the ... 50 Final Cut Pro X transitions featuring organic animations. Choose ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2
... by scientists belonging to the Northwestern University targeted at ... //The gene therapy, described in the January online issue ... Bohn and her laboratory group at Northwestern University Feinberg ... Medical Research Council Professor and director of the neurobiology ...
... Health has asked to stop SMART trial (Strategies for ... AIDS patients who are undergoing Anti-retroviral //therapy which recommends ... required contrasting to routine therapy which requires daily intake ... is aimed at reducing the side effects of the ...
... Commission of Australia has recommended a report which makes possible ... out referral from the physician. // ,The Australian ... they feel that the move will help to reduce the ... consultation straightly with the specialist will help the present situation ...
... man was very much disappointed when he was not accepted to ... to donate his sperm legally as the policy makers feel that ... to HIV, which could lead to transmission of the virus.// ... does not accept the discrimination against him and does not accept ...
... treatment of the fatal childhood cancer acute lymphoblastic leukemia ... according to researchers belonging to the St. Jude Children's ... the cure rate since 1962, when only 4% of ... more effective use of existing drugs and the incorporation ...
... Professor Susana Martinez-conde and her research team from Barrow Neurological ... movements occurring inside the eye even when the person ... proper visibility. ,Even when we are gazing at ... things visible and if these movement stops it leads to ...
Cached Medicine News:Health News:Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: